In Era of Research Cuts, Romance Blossoming Much Earlier Between Universities and Big Pharma
Engineering new pharmaceuticals is risky, achingly slow and astronomically expensive. While the estimates of how much it costs to get a drug into patients’ hands vary and are often disputed, Tufts University pegs the figure at north of $2.5 billion. In search of better ways to defray those costs and speed the path to success, Chicago’s elite research universities are partnering with the major pharmaceutical companies, ushering in a new era of early-phase collaboration. Read more.